Skip to main content
Equibles

BIOCON · Biocon Limited

Use BIOCON with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIOCON.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
371.00 INR +3.10 (+0.84%) At close · Nov 12
Rebalance outlook locked
Volume · Nov 12 350.87K Avg daily vol (3M) 435.55K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close371.00 INR Open371.50 INR Day365.20–372.05 INR 52W close326.60–440.70 INR Avg vol 30d181K Last earningsNov 4, 2026 DataJan 2020–Nov 2026

Latest documents

2026
Nov 4
Earnings call
Stronger second half expected with $400 million Brazil contract

Biocon Limited reported 2% year-on-year operating revenue growth in Q2FY27 and expects H2 to be stronger than H1. Its 10-year, $400 million Brazilian Pertuzumab contract is scheduled to begin supplies in Q4FY27.

6 source passages
Ladies and gentlemen, good day, and welcome to Biocon Limited Q2 FY27 Earnings Conference Call. In Q2FY27, the group delivered a 2% year-on-year growth in operating revenues. We expect H2 to be stronger than H1, supported by improving biosimilars momentum, as I talked about earlier, continued profitability improvement in generics, which we have demonstrated for the last couple of quarters and a progressive recovery at Syngene, which is demonstrated in Q2 over Q1. Biocon Biologics was recently awarded a landmark 10-year contract with a total contract value of $400 million under the Brazilian government's Productive Development Partnership, or the PDP program, as it is called, in partnership with Bahiafarma and Bionovis, as Kiran talked about earlier. Supplies to this program are scheduled to begin in Q4FY27. We are excited to bring biosimilar Pertuzumab to patients in Brazil. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▼3.3% 38.21B INR 251.00M INR '25 Q3 ▲12.8% 44.17B INR 3.44B INR '25 Q4 ▲14.8% 39.42B INR 314.00M INR '26 Q1 ▲19.6% 42.95B INR 845.00M INR '26 Q2 ▲9.2% 41.73B INR 1.44B INR '26 Q3 ▲2.3% 45.17B INR 1.26B INR '26 Q4 ▲10% 43.36B INR 1.41B INR '27 Q1 LATEST ▲2.2% 43.89B INR 413.00M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 326.60 INR Now 371.00 INR · 39% Range high 440.70 INR
vs 200-day avg -5% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:BIOCON +2.7% +5.6% -13.9% +5.4% -5.8%

Exchange listing

Market
XBOM
Ticker
BIOCON
ISIN
INE376G01013
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.biocon.com/
Investor relations
https://www.biocon.com/investor-relations/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-07-03 0.50 INR
2025-07-04 0.50 INR
2024-07-05 0.50 INR
2023-07-07 1.50 INR
2022-06-30 0.50 INR
2019-07-18 0.50 INR
2018-07-19 0.50 INR
2017-07-20 0.50 INR
2016-03-17 0.8333 INR
2015-04-09 0.8333 INR
2014-07-10 0.8333 INR
2012-07-05 0.8333 INR
2011-07-07 0.50 INR
2011-05-05 0.25 INR
2010-07-08 0.5833 INR

Upcoming investor events

DateEventType
2027-02-04 00:00 UTC Q3 FY 2026-27 Event
2027-05-06 00:00 UTC Q4 FY 2026-27 Event

Earnings calls

  • Earnings call · Q2 2027 2026-11-04 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-06 Transcript
    Earnings Call
  • Earnings call · Q4 2026 2026-05-08 Audio Transcript
    Biocon Limited Q4 FY26 Earnings Call